RT Journal Article
SR Electronic
T1 The effectiveness of grass, birch, and mugwort pollen allergen immunotherapy over 18 years: A national cohort study in Denmark
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.16.22282380
DO 10.1101/2022.11.16.22282380
A1 Peter Bager
A1 Gry Poulsen
A1 Jan Wohlfahrt
A1 Mads Melbye
YR 2022
UL http://medrxiv.org/content/early/2022/11/18/2022.11.16.22282380.abstract
AB Background Long-term effectiveness of pollen allergen immune therapy (AIT) for allergic rhinitis (AR) has been studied for different durations. We studied effectiveness over 18 years using nationwide register-data for Denmark.Methods A register-based cohort study using data on filled prescriptions, 1995-2018, Denmark. In a cohort of 1.1 million intranasal corticosteroid spray users (proxy for AR), we matched users treated with grass, birch or mugwort (GBM) AIT 1:2 with non-treated users on baseline year and 24 characteristics in the 3 years prior to baseline. The primary outcome was the odds ratio (OR) of using anti-allergic nasal spray during the pollen season in the treated vs. non-treated group modelled in a logistic generalized estimating equations analysis using an autoregressive correlation structure and adjusted for years since baseline (one year categories).Results Among 7,914 AR patients treated with GBM AIT, the OR of using nasal spray 0-5 years after baseline was reduced when compared with 15,520 non-treated AR individuals (0-2 years, odds ratio (OR) 0.81(0.76-0.85); 3-5 years, OR 0.82(0.77-0.87)), but was close to unity or higher thereafter (6-9 years, OR 0.96(0.91-1.03); 10-18 years, OR 1.15(1.06-1.24). In post-hoc analyses, results were more consistent for those who already had 3 of 3 baseline years of use (0-2 years, OR 0.59 (0.54-0.64); 3-5 years, OR 0.64 (0.59-0.71); 6-9 years, 0.82 (0.75-0.91); 10-18 years, 0.95 (0.84-1.08), and in patients using nasal spray in the last pollen season (0-2 years, OR 0.76 (0.72-0.80); 3-5 years 0.84 (0.78-0.91); 6-9 years, OR 0.94 (0.86-1.03); 10-18 years, 0.90 (0.81-1.00)) as opposed to patients who did not use nasal spray in the last pollen season. The post-hoc findings were likewise more consistent for eye drop and oral antihistamine users (secondary outcomes).Conclusion Patients treated with GBM AIT in routine care to a higher degree stopped using anti-allergic nasal spray 0-5 years after starting the standard three years of therapy. Post-hoc analyses suggested results were more consistent among patients with persistent AR.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from Aase og Ejnar Danielsens Fond (19-10-0208), Dagmar Marshalls Fond, Fonden til Lægevidenskabens Fremme (A.P. Møller og Hustru Chastine McKinney Møller 18-L-0194), Hartmann Fonden (A33348), and Helsefonden (16-B0320). Dr Bager was supported by a grant from Oak Foundation (OCAY-12-319). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Danish Data Protection Agency (no. 15/09765). According to Danish law, ethics approval is exempt for such research. Due to the nature of this research, there was no involvement of patients or members of the public in the design or reporting of this study. Direct dissemination to study participants is not possible. Permission from the Danish Health and Medicines Authority has been granted (no. 15/09765).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe data are available for research upon reasonable request to the Danish Health and Medicines Authority, Statistics Denmark, and the Research services for the Danish Health Data authority within the framework of the Danish data protection legislation and any required permission from relevant authorities.AITallergen immunotherapy;ARallergic rhinitis;GBMgrass-birch-mugwort;NSnasal spray;INSintranasal corticosteroid spray;GPgeneral practitioner.